FoxP3+CD4+ regulatory T cells (Tregs) suppress immune responses and their removal enhanced anti-tumor immunity, resulting in tumor regression in mice; therefore, Treg control has become a new target in cancer immunotherapy [4–6]. The gene discussed is FOXP3; the disease is neoplasm.